We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

22 hedge funds and large institutions have $3.23M invested in VistaGen Therapeutics in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

60% more capital invested

Capital invested by funds: $2.02M → $3.23M (+$1.22M)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

10% more funds holding

Funds holding: 20 → 22 (+2)

0.03% more ownership

Funds ownership: 0.32% → 0.35% (+0.03%)

Holders
22
Holders Change
+2
Holders Change %
+10%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SFM
Sphera Funds Management
Israel
+$144K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$84K
4
RC
RBF Capital
California
+$29K
5
DADC
D.A. Davidson & Co
Montana
+$26.7K

Top Sellers

1
SM
Sabby Management
Florida
-$133K
2
CA
Corrado Advisors
New Jersey
-$24.3K
3
BC
Bartlett & Co
Ohio
-$14K
4
BCWM
Bartlett & Co Wealth Management
Ohio
-$13.9K
5
UBS Group
UBS Group
Switzerland
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
1
Sphera Funds Management
Israel
$1.88M +$144K +4,155 +10%
II
2
Ibex Investors
Colorado
$260K +$11.6K +333 +6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$247K +$6.08K +175 +3%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$187K +$124K +3,555 +354%
DADC
5
D.A. Davidson & Co
Montana
$105K +$26.7K +767 +43%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$99K +$84K +2,416 New
LTFS
7
Ladenburg Thalmann Financial Services
Florida
$97K – – –
CA
8
Corrado Advisors
New Jersey
$62K -$24.3K -700 -32%
Parallax Volatility Advisers
9
Parallax Volatility Advisers
California
$61K – – –
Northern Trust
10
Northern Trust
Illinois
$36K – – –
RC
11
RBF Capital
California
$35K +$29K +833 New
FAIM
12
Financial Advocates Investment Management
Washington
$32K – – –
HighTower Advisors
13
HighTower Advisors
Illinois
$32K +$2.99K +86 +12%
GBA
14
Garrison Bradford & Associates
New York
$27K +$23.2K +667 New
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$22K +$18.5K +533 New
Citadel Advisors
16
Citadel Advisors
Florida
$21K +$17.6K +506 New
CWA
17
Clarus Wealth Advisors
Arizona
$14K – – –
PNC Financial Services Group
18
PNC Financial Services Group
Pennsylvania
$11K +$9.28K +267 New
CPA
19
Cowen Prime Advisors
New York
$5K +$3.93K +113 New
WOC
20
West Oak Capital
California
$685 – – –
SM
21
Sabby Management
Florida
– -$133K -4,783 Closed
BC
22
Bartlett & Co
Ohio
– -$14K -500 Closed
BCWM
23
Bartlett & Co Wealth Management
Ohio
– -$13.9K -500 Closed
UBS Group
24
UBS Group
Switzerland
– -$12K -443 Closed
SWP
25
Stratos Wealth Partners
Ohio
– -$1K -42 Closed

VTGN Hedge Fund Activity: Q2 2018 in Review

22 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2018, worth a combined $3.23M — up 60% from $2.02M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VTGN positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $144K. The largest seller was Sabby Management, exiting entirely with an estimated $133K sold.

  • 22 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2018, up from 20 in Q1 2018.
  • Funds reported $3.23M of VistaGen Therapeutics stock for Q2 2018, up 60% quarter-over-quarter.
  • 7 funds opened new VistaGen Therapeutics positions in Q2 2018 and 5 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2018 was Sphera Funds Management, an estimated $144K added.
  • The largest VistaGen Therapeutics seller in Q2 2018 was Sabby Management, an estimated $133K sold.

Based on aggregated 13F filings for Q2 2018.